A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trial
Primary result · ACR50Result — go to the resultAdjusted odds ratio 1.0 95% CI 0.6–1.6Authors' conclusion
Patients responded well to both treatments, with no clear advantage of abatacept vs adalimumab. Most patients tolerated their assigned therapies.
Study context
- Population
- Adults with early rheumatoid arthritis (RA), MTX-IR, dual seropositivity for ACPA and rheumatoid factor (RF), plus HLA-DRB1 shared epitope96% completed treatment
- Participants
- 338 adults
- Comparison
- Abatacept vs adalimumab
- Primary endpoint
- ACR50 in the SE-positive subgroup
- Follow-up
- Week 24
Methodological detailsphase 3, head-to-head, single-blind, global
- Phase 3
- Head-to-head
- Single-blind
- Global
Primary result
ACR50
Adjusted odds ratio
1.0
95% CI 0.6–1.6
By group
Abataceptvs Adalimumab
aOR 1.0 (95% CI 0.6–1.6)
As reported in the abstract
Further findings
Anti-CCP2, CRP and RF levels
- Decreased with both treatments
Immune modulation
- Differential impacts, including B-cell homeostasis
Patient-reported outcomes (PROs)
- Both treatments improved PROs, including pain
Safety
AEs
Serious AEs
Original publication
A head-to-head comparison of abatacept and adalimumab in adults with early and dual seropositive rheumatoid arthritis plus HLA-DRB1 shared epitope: results from the randomised phase 3 AMPLIFIED trial. Ann Rheum Dis. Published 9 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →